Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Pliant Therapeutics reported its third quarter 2025 financial results on November 6, 2025, highlighting operational progress and improved financial performance126.
The company completed enrollment in the Phase 1 open-label trial for PLN-101095, an oral dual integrin inhibitor targeted at checkpoint-resistant solid tumors. Interim results in one cohort showed a 50% objective response rate; full data across all cohorts are expected by the end of 2025126.
Research and development expenses decreased to $17.9 million for Q3 2025, down from $47.8 million in the previous year, largely due to the discontinuation of the BEACON-IPF trial126.
General and administrative expenses dropped to $10.3 million, and the net loss narrowed to $26.3 million compared to $57.8 million a year earlier168.
As of September 30, 2025, Pliant Therapeutics had $243.3 million in cash, cash equivalents, and short-term investments, partly due to cost-saving measures and the conclusion of the BEACON-IPF program1268.
The company completed a voluntary prepayment of its March 2024 loan with Oxford Finance, further improving its financial position168.
Close-out activities for the BEACON-IPF Phase 2b/3 trial are set to be completed in the fourth quarter of 2025; full results for this program are slated for future publication126.
Pliant Therapeutics plans to release data from the highest dose cohorts of the PLN-101095 trial by the end of 2025 and continues to evaluate strategic opportunities to create shareholder value126.
Sources:
1. https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-eb251vyy477n.html
2. https://www.globenewswire.com/news-release/2025/11/06/3183080/0/en/Pliant-Therapeutics-Provides-Corporate-Update-and-Reports-Third-Quarter-2025-Financial-Results.html
6. https://www.tipranks.com/news/company-announcements/pliant-therapeutics-reports-improved-q3-2025-results
8. https://www.marketscreener.com/news/pliant-therapeutics-q3-net-loss-narrows-to-26-3-mln-ce7d5cd3da81f32d